AusCann (ASX:AC8) engages knoell Animal Health to develop CPAT-01 U.S Program

Highlights

  • AusCann has entered into an agreement with knoell Animal Health LLC to advise on the CPAT-01 clinical program and U.S regulatory strategy.
  • CPAT-01 is a Phase 2 pharma veterinary drug candidate obtained from THC and CBD extracts, in development for FDA-CVM approval for pain and inflammation in dogs.
  • Veterinary pain and inflammation market is valued over US$1billion globally and there’s an unmet need for safe and viable treatment options for dogs suffering from painful conditions.

Today, ASX-listed Australian based pharmaceutical Company AusCann Group Holdings Limited (ASX:AC8) declared via an announcement that it has struck a deal with knoell Animal Health LLC to advise on the CPAT-01 clinical program and U.S regulatory strategy ahead of the Company’s PSC meeting with the FDA-CVM.

CPAT-01 is a Phase 2 pharmaceutical veterinary drug candidate obtained from THC and CBD extracts, in development for FDA-CVM approval for pain and inflammation in dogs.

                       

Why ASX stocks SXY, AC8, PNI, MKR, OSH on investors radar today?

 

The announcement revealed that Laura Treml will be AusCann’s technical manager for the project, with more than 20 years of experience in companion animal practice and veterinary drug development with Companies such as Bayer and Aratana Therapeutics. Besides, Treml has managed a number of canine pain and anti-inflammatory development programs which has included the U.S FDA approval for Nocita (a long lasting analgesic for post-surgical pain in dogs), and the EU marketing authorisation for Galliprant.

According to the Group, the scope pf work in the agreement includes:

  • Participating in the Company’s expert clinical advisory group to provide guidance for the design and technical requirements for a Phase 2C clinical effectiveness program for CPAT-01 in accordance with Veterinary Medicinal Products Good Clinical Practices (VICH GL9);
  • Offering consulting support for the regulatory strategy with the FDA-CVM ahead of the Company’s PSC in accordance with the Code of Federal Regulations Title 21 and applicable FDA guidance for industry.

About knoell Animal Health LLC

Knoell is a USA-based consultancy company with expertise in all useful technical areas offers international product development and registration services for the animal health industry. The technical staff of animal health team at knoell is spread across three continents: North America, Asia and Europe.

Bottomline:

The veterinary pain and inflammation market is valued over US$1billion globally and there’s an unmet need for safe and viable treatment options for dogs suffering from painful conditions. The agreement signed with the US based firm will provide AusCann Group the best support in the development of CPAT-01 and towards approval in the USA.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK